Cargando…

Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients

Detalles Bibliográficos
Autores principales:	Zayet, Souheil, Klopfenstein, Timothee, Mercier, Julien, Kadiane-Oussou, N’dri Juliette, Lan Cheong Wah, Ludovic, Royer, Pierre-Yves, Toko, Lynda, Gendrin, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221233/ https://www.ncbi.nlm.nih.gov/pubmed/32410112 http://dx.doi.org/10.1007/s15010-020-01442-3

Ejemplares similares

COVID-19: comparative clinical features and outcome in 114 patients with or without pneumonia (Nord Franche-Comte Hospital, France)
por: Kadiane-Oussou, N’dri Juliette, et al.
Publicado: (2020)

Diarrhea: An underestimated symptom in Coronavirus disease 2019
por: Klopfenstein, Timothée, et al.
Publicado: (2020)

Angioedema and COVID-19: A New Dermatological Manifestation?
por: Royer, Pierre-Yves, et al.
Publicado: (2021)

New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France
por: Klopfenstein, Timothée, et al.
Publicado: (2020)

Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster
por: Zayet, Souheil, et al.
Publicado: (2020)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Features of anosmia in COVID-19
por: Klopfenstein, T., et al.
Publicado: (2020)

Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
por: Klopfenstein, Timothée, et al.
Publicado: (2020)

Third of patients have gustatory dysfunction 9 months after SARS-CoV-2 infection: the ANOSVID study
por: Klopfenstein, Timothée, et al.
Publicado: (2022)

Asthma and Cacosmia Could Be Predictive Factors of Olfactory Dysfunction Persistence 9 Months after SARS-CoV-2 Infection: The ANOSVID Study
por: Tipirdamaz, Can, et al.
Publicado: (2022)

Sensibilité, spécificité et valeurs prédictives des signes fonctionnels de l’infection par SARS-CoV-2
por: Zayet, S., et al.
Publicado: (2020)

Pneumopathies graves liées au COVID-19 : facteurs prédictifs de mortalité après traitement par tocilizumab
por: Kadiane-Oussou, N., et al.
Publicado: (2020)

Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab’s Place in COVID-19 Pneumonia
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Recurrence of COVID-19 after recovery ? A case series in health care workers, France
por: Zayet, Souheil, et al.
Publicado: (2021)

Shigella sonnei, an emerging multidrug-resistant sexually transmitted pathogen in Franche-Comté, France
por: Zayet, Souheil, et al.
Publicado: (2021)

Cohorte de 206 patients avec pneumopathie à SARS-CoV-2 : le tocilizumab diminue la mortalité et/ou le recours à la ventilation mécanique invasive
por: Klopfenstein, T., et al.
Publicado: (2020)

Campylobacter fetus Invasive Infections and Risks for Death, France, 2000–2021
por: Zayet, Souheil, et al.
Publicado: (2023)

COVEVOL: Natural Evolution at 6 Months of COVID-19
por: Messin, Louise, et al.
Publicado: (2021)

Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
por: Zayet, Souheil, et al.
Publicado: (2021)

Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
por: Klopfenstein, Timothée, et al.
Publicado: (2022)

Potential Mechanisms for COVID-19 Induced Anosmia and Dysgeusia
por: Eshraghi, Adrien A., et al.
Publicado: (2020)

Anosmia and dysgeusia in COVID-19: A systematic review
por: Carrillo-Larco, Rodrigo M., et al.
Publicado: (2020)

Can symptoms of anosmia and dysgeusia be diagnostic for COVID‐19?
por: Zahra, Syeda Anum, et al.
Publicado: (2020)

Anosmia and dysgeusia as markers of severity and prognosis in COVID-19
por: Carpio-Orantes, Luis Del, et al.
Publicado: (2023)

A Comparative Systematic Review of COVID-19 and Influenza
por: Osman, Molka, et al.
Publicado: (2021)

Increased COVID-19 Severity among Pregnant Patients Infected with SARS-CoV-2 Delta Variant, France
por: Zayet, Souheil, et al.
Publicado: (2022)

Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma
por: Da Silva, Léa, et al.
Publicado: (2023)

Pathogenesis and progression of anosmia and dysgeusia during the COVID-19 pandemic
por: Krishnakumar, Hari N., et al.
Publicado: (2022)

Stellate Ganglion Block for Anosmia and Dysgeusia Due to Long COVID
por: Chauhan, Gaurav, et al.
Publicado: (2022)

Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France
por: Zayet, Souheil, et al.
Publicado: (2021)

Simultaneous co-infection with Omicron (B.1.1.529) and Delta (21A/478K.V1) SARS-CoV-2 variants confirmed by whole genome sequencing
por: Zayet, Souheil, et al.
Publicado: (2022)

Lactobacillus rhamnosus a cause of Gram-positive rods bacteremia after prophylactic probiotic consumption
por: Zayet, Souheil, et al.
Publicado: (2023)

Self-reported anosmia and dysgeusia as key symptoms of coronavirus disease 2019
por: Lee, Daniel J., et al.
Publicado: (2020)

Recurrent obstructive prostatitis revealing granulomatosis with polyangiitis
por: Clerc, Melitine, et al.
Publicado: (2021)

Antibiotics and Therapeutic Agent Prescription in COVID-19 Management
por: Zayet, Souheil, et al.
Publicado: (2022)

Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection
por: Lao, Wilson P., et al.
Publicado: (2020)

Transient Anosmia and Dysgeusia in COVID-19 Disease: A Cross Sectional Study
por: Ali, Fatema Ahmed, et al.
Publicado: (2023)

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales
por: Bouiller, Kévin, et al.
Publicado: (2022)

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
por: Klopfenstein, T., et al.
Publicado: (2020)

Anosmia and Dysgeusia in the Absence of Other Respiratory Diseases: Should COVID-19 Infection Be Considered?
por: Lorenzo Villalba, Noel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8vpq4l7k3qlm21rcbl94tl4b93